Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network
about
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell TransplantationImproved accuracy of acute graft-versus-host disease staging among multiple centersAdvances in predicting acute GVHDDisease severity and mortality can be independently regulated in a mouse model of experimental graft versus host diseaseAcute graft-versus-host disease: a bench-to-bedside update.Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.Improved survival after acute graft-versus-host disease diagnosis in the modern era.The biology of graft-versus-host disease: experimental systems instructing clinical practice.Prognostic value of response after upfront therapy for acute GVHDGraft-versus-host disease: state of the science.Advances in graft-versus-host disease biology and therapy.Pathogenesis and management of graft-versus-host disease.Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.Graft-versus-host disease treatment: predictors of survival.Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcomeInflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studySingle-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.Management of acute graft-versus-host disease in children.Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.Mesenchymal stromal cells: a new tool against graft-versus-host disease?Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Have we improved in preventing and treating acute graft-versus-host disease?Implications of TNF-α in the pathogenesis and management of GVHDPaediatric use of mycophenolate mofetil.Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival.Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationAdvances in the treatment of acute graft-versus-host disease.Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells.Treatment and management of graft-versus-host disease: improving response and survival.Acute graft-versus-host disease: from the bench to the bedside.Combined nifuroxazide and SAT05f therapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.
P2860
Q26740251-D8C25CEC-22EF-4CC5-802E-41B21488DFF0Q26999931-7CA202DA-2CE1-4AB7-BEBA-13F399A8BEA9Q27021123-EBF11762-1EB2-434A-B93D-5DE9643C36DFQ27314927-C81F4927-FA19-42D2-AAB1-ABA8B15D6393Q27687130-B71B2636-6C13-4A84-A8DD-062C0C298773Q33394786-6D070F30-B345-416A-A00A-DAC7A778C6A3Q33806054-D5E868CE-84EF-4202-9E7F-DD2AE1FBD365Q33816027-048FD20E-87AE-4E1B-8689-6E6912B3B3D8Q33917175-9BCD7E5A-AD40-4295-94C9-70CD81FB318CQ33964701-ABDCEA5E-B515-48D0-81FE-8C611107B687Q33977923-46C44E28-83C7-4B33-88D4-8A0259C445CFQ34031916-9EAD0499-5685-4C04-A75A-A873ECA96D77Q34077479-037880EC-86F0-4896-A138-586E141AEE9BQ34093615-EB310A94-3CDF-4544-87AA-C151E1A770E5Q34205096-16B3B489-0852-4CC9-8BEB-B7EF02120B22Q34388640-CE04AB25-2796-4852-9EF8-CD058517FBB4Q34441886-FAF53907-F78A-4243-B1EE-360A309D7D7FQ34551192-43A4F5ED-F5E4-4181-B937-B9252748597EQ34640239-324CCA64-8779-48E0-B016-BF6CB738D130Q34666851-D0B87B32-404A-47D7-B5CE-B7B88427974CQ34684038-58B2A9B0-50E5-4F9D-ACE1-B03533C386C3Q35177453-CC3EA3F3-97DC-40AC-B5E9-3EAE00DEA8B8Q35193740-6FE3262C-DDE0-4A9B-B36B-A1A650E10171Q35583009-B9A9FB62-A8C3-4EC2-ADD5-102390FB4379Q35588944-F3BE6524-F0D6-4649-AEBB-952CCA42588CQ35673668-F45EE220-FC2F-45F1-8679-58898240D4B4Q35848391-B1A0B3D5-D35A-4142-BED4-F7C9E40397C6Q35909700-521F9BA1-E949-4C77-88F1-2E12AC9D6C50Q36113205-F7D16412-81F7-41AC-8239-73A8E5105EBBQ36203692-959C692F-2203-4C4F-AAFF-E2BA81850CB9Q36370782-4F99F7F1-0130-4EE3-9B94-07D9BFB755EFQ36562448-9A9EAE1A-3A9C-41A6-93C9-27C939ACEF64Q36726854-05744A7E-47E3-451D-8B67-D5DBFC291153Q36841805-0A7C6D74-C213-4B12-B83A-D511FC937E4DQ36891433-EFA22F27-4A53-44F2-84E3-92BDCB3F90A9Q37191057-F427547F-3094-4D72-BF32-91DC4711CB83Q37223366-889B3DA1-A602-4209-B3B4-3C1611469DD5Q37371836-19772FC5-2422-455A-9469-B50DD34DEE84Q37420496-C84569B6-A7AD-4833-99E9-2F5A74FF5C20Q37603497-D5A7A2BF-4CD3-44EC-B514-F7CA250DB264
P2860
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Etanercept, mycophenolate, den ...... splant Clinical Trials Network
@en
Etanercept, mycophenolate, den ...... plant Clinical Trials Network.
@nl
type
label
Etanercept, mycophenolate, den ...... splant Clinical Trials Network
@en
Etanercept, mycophenolate, den ...... plant Clinical Trials Network.
@nl
prefLabel
Etanercept, mycophenolate, den ...... splant Clinical Trials Network
@en
Etanercept, mycophenolate, den ...... plant Clinical Trials Network.
@nl
P2093
P2860
P1433
P1476
Etanercept, mycophenolate, den ...... splant Clinical Trials Network
@en
P2093
Amin M Alousi
Blood and Marrow Transplant Clinical Trials Network
Brandon Hayes-Lattin
Brent R Logan
Daniel J Weisdorf
Javier Bolaños-Meade
John E Levine
John R Wingard
Marcelo Pasquini
Mary M Horowitz
P2860
P304
P356
10.1182/BLOOD-2009-03-212290
P407
P577
2009-05-14T00:00:00Z